(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Catholic influencer shares death of 5-year-old son from 'severe' flu - 2Mom finds out she has cancer after noticing something was off while breastfeeding
- 3Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- 4Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 5She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Beating Wellbeing Difficulties: Individual Victories in Health
- Instructions to Pick the Ideal SUV Size for Seniors
- Select Your Definitive Pizza Decision
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
- A Manual for Nations with Extraordinary Food
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Vote in favor of your Number one natural product
